BioNxt Solutions Reports Progress on BNT23001 Development for Multiple Sclerosis Treatment
9.12.2024 03:05:00 CET | ACCESS Newswire | Press release
VANCOUVER, BC / ACCESSWIRE / December 9, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery systems, has achieved key milestones in the development of BNT23001, its proprietary sublingual thin-film (OFD) formulation of Cladribine for the treatment of Multiple Sclerosis (MS). These achievements in 2024 lay the groundwork for clinical trials and regulatory submissions in 2025, reinforcing BioNxt's commitment to advancing patient-centric therapeutic solutions.
2024 Milestones: Establishing a Strong Foundation for Cladribine Thin-Film Development
Preclinical Success: BNT23001 demonstrated high absorption rates of Cladribine through sublingual delivery in pharmacokinetic (PK) studies conducted in animal models. These studies confirmed the product's bioequivalence to the originator therapy, Mavenclad®, and validated the thin-film's rapid absorption and safety profile. Toxicity studies further demonstrated no adverse local effects, highlighting the viability of the sublingual delivery approach.
Advancements in Manufacturing: BioNxt successfully transferred the BNT23001 production process to its GMP-certified manufacturing partner, Gen-Plus GmbH & Co KG in Munich (Germany), ensuring readiness for clinical batch production. This milestone supports the Company's plan to initiate clinical trials in 2025 with reliable, high-quality product supply.
Strengthened Intellectual Property Position: A favorable International Preliminary Report on Patentability (IPRP) confirmed BNT23001's novelty, inventive step, and industrial applicability, underscoring its unique value in MS treatment. The Company has initiated patent nationalization in major jurisdictions, including Europe, the United States, and Canada, with patent grants anticipated in several regions by mid-2025.
2025 Roadmap: Advancing BNT23001 into Clinical Trials
Manufacturing Clinical Batches: BioNxt will complete GMP manufacturing and Qualified Person (QP) release of clinical trial batches in the second quarter of 2025. This step is critical for the successful initiation of human studies.
Regulatory Filings and Approvals: The Company plans to submit the Investigational Medicinal Product Dossier (IMPD) to European regulatory authorities by mid-2025, paving the way for clinical trial approval. These regulatory submissions will include data from preclinical studies and stability assessments conducted at the manufacturing site.
Clinical Study to Validate Performance: BioNxt aims to launch a pilot clinical study in the latter half of 2025. This trial will compare the efficacy, bioavailability, and safety of BNT23001 to Mavenclad®, the originator tablet product, positioning the thin-film formulation as a patient-friendly alternative.
Ongoing Patent Protection: In addition to continuing the patent nationalization process, BioNxt expects granted patents in key regions to strengthen its intellectual property portfolio and provide competitive advantages as the product moves toward commercialization.
BNT23001: Advancing Toward Clinical Validation for MS Treatment
BNT23001 offers a novel approach to MS management by addressing limitations in traditional oral therapies. Its sublingual thin-film format provides:
• Convenience: Easy-to-use and portable, ideal for patients with difficulty swallowing or active lifestyles.
• Rapid Absorption: Direct delivery through the sublingual mucosa for faster therapeutic action.
• Improved Compliance: A patient-friendly alternative designed to enhance adherence to prescribed regimens.
By delivering these advantages, BNT23001 aligns with BioNxt's mission to improve outcomes for patients living with chronic diseases like MS.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablets)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity.
With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.
BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.
Investor Relations & Media Contact
Hugh Rogers, Co-Founder, CEO and Director
Email: investor.relations@bionxt.com
Phone: +1 780-818-6422
Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt-solutions
Instagram: https://www.instagram.com/bionxt
Cautionary Statement Regarding "Forward-Looking" Information
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the development, testing, regulatory approval, and commercialization of BNT23001, as well as projected milestones for 2025. These statements are based on current expectations and assumptions but involve risks and uncertainties that could cause actual results to differ materially. These risks include clinical trial outcomes, regulatory delays, manufacturing challenges, intellectual property issues, market competition, and changes in laws or market conditions. The Company undertakes no obligation to update or revise forward-looking statements, except as required by law. For more information, refer to the "Risk Factors" section of the Company's filings at www.sedarplus.ca.
Trademarks: Mavenclad® is a registered trademark of EMD Serono, Inc. BioNxt Solutions Inc. is not affiliated with or endorsed by EMD Serono.
SOURCE: BioNxt Solutions Inc.
View the original press release on accesswire.com
BioNxt Solutions Inc.
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Formerra to Supply Foster Medical Compounds in Europe29.1.2026 15:00:00 CET | Press release
Expanded agreement infuses Formerra's European healthcare polymer portfolio with life-saving Foster® compounds. PUTNAM, CT AND ROMEOVILLE, IL / ACCESS Newswire / January 29, 2026 / Formerra and GEON® Performance Solutions today announced an agreement that designates Formerra as the preferred distributor of Foster®, LLC medical compounds in Europe. This adds to Formerra's current distribution of these materials in North and South America, enabling Formerra to now support customers who need the same product in all regions. Following GEON's January 2025 acquisition of Foster, the agreement builds on Formerra's long-standing, global partnership with GEON for flexible and rigid PVC and filled polypropylene materials. "Bringing Foster's medical-grade portfolio to Europe strengthens our ability to support healthcare manufacturers across the region with specialized compounds and the local expertise they need to navigate complex regulatory environments," said Kelly Wessner, Vice President, Key
Innodata Selected by Palantir to Accelerate Advanced Initiatives in AI-Powered Rodeo Modernization29.1.2026 14:30:00 CET | Press release
Innodata's data engineering and annotation capabilities support Palantir's expanding AI platform deployments for event analytics NEW YORK, NY / ACCESS Newswire / January 29, 2026 / INNODATA INC. (Nasdaq:INOD) today announced that it has been selected to provide high-quality training data and data engineering services to Palantir Technologies (Nasdaq:PLTR), supporting Palantir's AI-enabled platforms for rodeo event analysis. In support of Palantir's partnership with rodeo operations, Innodata is now further empowering these customers by providing them with specialized annotation and data engineering for thousands of hours of rodeo video footage. This work enables computer vision models to detect animals, riders, and skeleton joints, allowing for the automated calculation and display of performance metrics in bull riding, bronc riding, bareback riding and barrel racing. Innodata will be providing specialized annotation, multimodal data engineering, and generative-AI workflow support for
Sadie Launches Cloudbeds Integration to Automate Guest Calls and Reservation Management with Voice AI28.1.2026 17:25:00 CET | Press release
MONTRÉAL, QUEBEC / ACCESS Newswire / January 28, 2026 / Sadie, the voice AI agent for the hospitality industry, today announced a new integration with Cloudbeds, the hospitality industry's leading unified platform, enabling hotels to automate guest calls while increasing direct bookings and freeing staff to focus on on-property service. Through the integration, Cloudbeds-powered hotels can deploy Sadie as an intelligent voice agent that answers calls instantly, shares real-time rates and availability, and creates and manages reservations directly within the Cloudbeds platform. Designed as an always-on extension of the front desk, Sadie ensures guest calls are answered instantly, day or night. From sharing real-time rates and availability to creating and modifying reservations, handling service requests, and assisting with overnight room lockouts, Sadie delivers immediate, multilingual support for both guests and hotel teams. By handling high-volume and after-hours calls, Sadie reduces
Power to Hydrogen Appoints David Bow as Chief Strategy Officer to Scale International Expansion28.1.2026 15:00:00 CET | Press release
Industry Veteran Brings 25+ Years Of Senior Leadership In Hydrogen And Industrial Decarbonization COLUMBUS, OH / ACCESS Newswire / January 28, 2026 / Power to Hydrogen (P2H2), a developer of industrial-scale anion exchange membrane (AEM) electrolyzers designed for low-cost green hydrogen production, today announced that industry veteran David Bow has joined the company as Chief Strategy Officer. Bow will lead P2H2's corporate and commercial strategy as the company expands its industrial deployments and scales its go-to-market efforts in North America and Europe. His scope includes strategic partnerships, market entry and segmentation, commercial growth priorities, and alignment of product roadmap and validation plans with customer and financing requirements. Bow brings more than 25 years of senior leadership experience across hydrogen and industrial energy, including executive roles spanning commercialization, strategy, and scaling. He previously led Plug Power's Electrolyzer Solutions
GoodData Brings Faster BI Modernization to Make Analytics AI-Ready28.1.2026 15:00:00 CET | Press release
Modernize legacy BI without disruption. Refactor business logic into a governed semantic layer while keeping dashboards online. SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / January 28, 2026 / GoodData, the AI-powered analytics and decision intelligence platform, today introduced AI-driven BI modernization, a new approach that helps organizations move off legacy BI faster while preserving critical reporting workflows. Early outcomes teams can expect AI-driven BI modernization separates business logic from dashboards and standardizes it in a governed semantic layer. This improves performance today and creates a stronger baseline for AI-driven use cases tomorrow. Expected results include: 2-5× faster iteration cycles for delivering new analytics Dashboards that load up to 10× faster by removing inefficient calculations and duplication Consistent, reusable metrics governed centrally and applied across teams and tools AI-ready analytics with clean, standardized logic that AI agents and aut
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom